Among patients with ovarian cancer, 8% have BRCA1 mutation, 6% have BRCA2 mutations, 6% have somatic BRCA1/2 mutations, and 10% have BRCA1 promoter inactivation [3]. This evidence concerns the gene BRCA2 and ovarian carcinoma.